Enhancement of Number of Ovulations by Administration of a Pyrimidine Compound with Potentiating Activity of Angiogenesis in Mice Superovulated by PMSG and hCG

Abstract

We evaluated the influence of the administration of a synthesized heterocyclic pyrimidine compound, 2-piperadino-6-methyl-5-oxo-5, 6-dihydro(7H) pyrrolo-[3, 4-d] pyrimidine (MS-818), which has promoting activity of basic fibroblast growth factor(bFGF)-induced angiogenesis, on the number of ovulations in mice (Jcl:ICR strain) superovulated with pregnant mare's serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG). When injected with PMSG and hCG, ovulation failed to be induced in 13.5% of mice, but all of those injected with MS-818 in addition to PMSG and hCG, responded to the stimulation and superovulated. There was also a significant increase in superovulatory response in the mice injected with MS-818 compared with those injected with saline. The mean actual number of ovulations for mice injected with 0 (saline) or 50 μg of MS-818 for 3 days was 13.1 ± 2.1 and 26.9 ± 4.2, respectively, indicating that MS-818 affected the actual number of ovulations. Subcutaneous injection of MS-818 resulted in more actual ovulations than intraperitoneal injection. There was no difference between the control (saline) and MS-818-injected groups in the proportion of ova fertilizing and cleaving to the blastocyst stage in vitro.